API manufacturers spend years developing a synthesis route. That route contains process steps, impurity controls, and material specifications that competitors would love to copy. At the same time, the FDA needs to see all of that detail before it lets a drug reach patients. These two needs pull in opposite directions, and the drug master file is the mechanism that resolves the conflict.
A drug master file, or DMF, is a submission made to the FDA that contains confidential information about the facilities, processes, or materials used to manufacture, package, or store a human drug. The API supplier files it directly. The buyer never sees the contents. The FDA does.
Why This System Exists
An API supplier and a finished-dose pharma company are rarely the same business, and they rarely want to share the same information. The pharma company needs proof that its API source is safe, consistent, and compliant. The supplier needs to keep its synthesis route and impurity data away from competitors, including the buyer itself in some cases.
The DMF lets both things happen at once. Arbor Pharmchem, for example, can submit full manufacturing detail to the FDA on a product like an API or intermediate, while the customer buying that material only needs a reference number to point the FDA toward it. Nobody outside the agency has to open the file. This is also why nitrosamine impurity data and other sensitive quality information typically live inside the DMF rather than in a data package handed across the table.
Types of FDA Drug Master Files
The FDA sorts DMFs into five categories, though one dominates in practice.
- Type I covered manufacturing facilities and equipment. The FDA phased this category out years ago.
- Type II is the one that matters for API suppliers. It covers the drug substance itself, drug substance intermediates, and the materials used to make them. Most CDMOs and API manufacturers file under this type.
- Type III covers packaging materials, such as containers and closures.
- Type IV covers excipients, colorants, flavors, and similar materials that go into a formulation but aren’t the active ingredient.
- Type V covers FDA-accepted reference information that doesn’t fit the other four categories.
If a customer asks a supplier whether it has a DMF, they almost always mean Type II.
DMF Versus European ASMF
Companies buying API for markets outside the US run into a different system in Europe. The EMA equivalent is called an Active Substance Master File, or ASMF.
The two documents aren’t built the same way. A US DMF is one confidential file, held entirely by the FDA. An ASMF is split into two parts. The Applicant’s Part, often called the open part, goes to the pharmaceutical company submitting the marketing authorization application. The Restricted Part stays with the regulator and contains the sensitive manufacturing detail.
So a supplier working across both regions needs to maintain two different document structures for the same underlying process, one fully closed and one partially open. Buyers sourcing for global filings should ask suppliers directly whether they maintain both a US DMF and an EU ASMF, since having one doesn’t guarantee the other.
How a Letter of Authorization Works
A pharma company preparing a New Drug Application or an Abbreviated New Drug Application needs to reference its API supplier’s DMF, but it can’t open the file and read it. The connection happens through a document called a Letter of Authorization, or LoA.
The supplier writes this letter and files it with the FDA. It names the specific customer and the specific application the customer is allowed to reference. Once that’s on file, the FDA can pull up the supplier’s DMF while reviewing the customer’s NDA or ANDA, without the customer ever seeing the contents.
Without an LoA on record, referencing a DMF number in a submission does nothing. The FDA has no authority to look at a file nobody has given them permission to connect to that application. Buyers should confirm before filing that their supplier has actually submitted the LoA naming them, not just that a DMF number exists somewhere.
Why Supplier Selection Around This Matters
A common misunderstanding is that the FDA approves or rejects a DMF on its own. It doesn’t. The agency only reviews a DMF when it’s tied to an active IND, NDA, or ANDA submission from a customer. There’s no independent approval status to check.
That makes the quality of the DMF someone else’s problem until it isn’t. If the impurity studies are thin, or the chiral purity data doesn’t hold up, the FDA can send the customer a Complete Response Letter and stop the drug’s approval cold, even though the customer did nothing wrong on their end. The weak link was the supplier’s filing.
This is where supplier due diligence pays off before a project starts, not after a rejection letter arrives. A supplier with an experienced regulatory affairs team, eCTD-formatted submissions, and a track record of clean CMC data reduces that risk substantially. Arbor Pharmchem’s regulatory team builds DMF submissions with this in mind, working alongside customers’ own regulatory staff to keep IND, NDA, and ANDA timelines on track rather than stalled by an incomplete filing.
Common Questions
Does the FDA approve a drug master file on its own?
No. The FDA only reviews a DMF in connection with an IND, NDA, or ANDA that references it through a Letter of Authorization.
Is filing a DMF required by law?
No, it’s voluntary. In practice, it’s the standard way API suppliers protect their manufacturing IP while still supporting customer regulatory filings.
Can a customer read a supplier’s DMF directly?
No. The contents stay confidential with the FDA. Customers only see what the supplier chooses to share separately, such as a certificate of analysis or a quality agreement.
Looking for an API supplier with an active DMF and a regulatory team that can support your IND, NDA, or ANDA filing directly? Reach out to the Arbor Pharmchem team to discuss your project.
